Skip to main content
SpringerLink
Log in

Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

Elevated plasma CT-pro-vasopressin (copeptin) has been described as biomarkers for type 2 diabetes (T2D) and the metabolic syndrome (MetS), which, however, was not confirmed by all studies. Here, we analyzed the association of copeptin with T2D, MetS and MetS components in the population-based KORA F4 study. Plasma copeptin concentrations were analyzed in 1,554 study participants. We used fractional polynomial selection procedures to check for nonlinearity of the associations between copeptin and T2D and HbA1c, respectively. In logistic regression models, we investigated associations between copeptin and T2D, MetS and its components according to IDF criteria. In the fractional polynomial approach, linear models fitted best for copeptin. In multivariable adjusted models, copeptin as a continuous variable was associated with T2D and HbA1c only in men (OR = 1.38 per standard deviation, 95 % CI 1.13–1.70 for T2D). Comparing the top quartile Q4 versus Q1–3, elevated copeptin was associated with T2D (OR 2.70, 95 % CI 1.60–4.59) in men but not in women (OR 0.98, 95 % CI 0.52–1.83). Copeptin was not significantly associated with MetS, central obesity, triglycerides and reduced HDL cholesterol. A significant association with copeptin was observed for hypertension in women (OR 1.59, 95 % CI 1.08–2.33) and glucose dysfunction according to IDF criteria in men (OR 1.63, 95 % CI 1.14–2.34). In the KORA F4 study, copeptin was significantly associated with T2D only in men, whereas hypertension was associated with copeptin in women. No other components of the MetS were related to elevated copeptin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Morgenthaler NG (2010) Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 16(Suppl 1):S37–S44. doi:10.1111/j.1751-7133.2010.00177.x

    Article  CAS  PubMed  Google Scholar 

  2. Holmes CL, Landry DW, Granton JT (2004) Science review: vasopressin and the cardiovascular system part 2—clinical physiology. Crit Care 8(1):15–23. doi:10.1186/cc2338

    Article  PubMed Central  PubMed  Google Scholar 

  3. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A (2007) Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148(5):2075–2084

    Article  CAS  PubMed  Google Scholar 

  4. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52(1):112–119. doi:10.1373/clinchem.2005.060038

    Article  CAS  PubMed  Google Scholar 

  5. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, Kullo IJ (2009) Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 94(7):2558–2564. doi:10.1210/jc.2008-2278

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O (2011) Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 96(7):E1065–E1072. doi:10.1210/jc.2010-2981

    Article  PubMed  Google Scholar 

  7. Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation 121(19):2102–2108. doi:10.1161/CIRCULATIONAHA.109.909663

    Article  PubMed Central  PubMed  Google Scholar 

  8. Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ (2012) Sex differences in the association between plasma copeptin and incident type 2 diabetes: the prevention of renal and vascular endstage disease (PREVEND) study. Diabetologia 55(7):1963–1970. doi:10.1007/s00125-012-2545-x

    Article  CAS  PubMed  Google Scholar 

  9. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K, Blankenberg S (2010) Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 5(4):e10100. doi:10.1371/journal.pone.0010100

    Article  PubMed Central  PubMed  Google Scholar 

  10. Then C, Kowall B, Lechner A, Meisinger C, Heier M, Koenig W, Peters A, Thiery J, Rathmann W, Seissler J (2013) Plasma copeptin levels are inversely associated with intima-media-thickness in men: the population-based KORA F4 study. Cardiovasc Diabetol 12(1):168. doi:10.1186/1475-2840-12-168

    Article  PubMed Central  PubMed  Google Scholar 

  11. Seissler J, Feghelm N, Then C, Meisinger C, Herder C, Koenig W, Peters A, Roden M, Lechner A, Kowall B, Rathmann W (2012) Vasoregulatory peptides pro-endothelin-1 and pro-adrenomedullin are associated with metabolic syndrome in the population-based KORA F4 study. Eur J Endocrinol 167(6):847–853. doi:10.1530/EJE-12-0472

    Article  CAS  PubMed  Google Scholar 

  12. Rathmann W, Strassburger K, Heier M, Holle R, Thorand B, Giani G, Meisinger C (2009) Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 26(12):1212–1219. doi:10.1111/j.1464-5491.2009.02863.x

    Article  CAS  PubMed  Google Scholar 

  13. Meisinger C, Ruckert IM, Rathmann W, Doring A, Thorand B, Huth C, Kowall B, Koenig W (2011) Retinol-binding protein 4 is associated with prediabetes in adults from the general population: the cooperative health research in the region of Augsburg (KORA) F4 study. Diabetes Care 34(7):1648–1650. doi:10.2337/dc11-0118

    Article  PubMed Central  PubMed  Google Scholar 

  14. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46(2):182–189. doi:10.1007/s00125-002-1025-0

    CAS  PubMed  Google Scholar 

  15. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644

    Article  CAS  PubMed  Google Scholar 

  16. Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O (2013) Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond) 37(4):598–603. doi:10.1038/ijo.2012.88

    Article  CAS  Google Scholar 

  17. Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, Groenier KH, Struck J, de Jong PE, Bilo HJ, Kleefstra N, Gansevoort RT (2013) Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. doi:10.1007/s00125-013-2922-0

    PubMed  Google Scholar 

  18. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116(3):257–263. doi:10.1042/CS20080140

    Article  CAS  Google Scholar 

  19. Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R (2013) Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 36(11):3639–3645. doi:10.2337/dc13-0683

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Spruce BA, McCulloch AJ, Burd J, Orskov H, Heaton A, Baylis PH, Alberti KG (1985) The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol (Oxf) 22(4):463–468

    Article  CAS  Google Scholar 

  21. Wang YX, Edwards RM, Nambi P, Stack EJ, Pullen M, Share L, Crofton JT, Brooks DP (1993) Sex difference in the antidiuretic activity of vasopressin in the rat. Am J Physiol 265(6 Pt 2):R1284–R1290

    CAS  PubMed  Google Scholar 

  22. Enhorning S, Leosdottir M, Wallstrom P, Gullberg B, Berglund G, Wirfalt E, Melander O (2009) Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr 89(1):400–406. doi:10.3945/ajcn.2008.26382

    Article  PubMed  Google Scholar 

  23. Stallone JN (1993) Role of endothelium in sexual dimorphism in vasopressin-induced contraction of rat aorta. Am J Physiol 265(6 Pt 2):H2073–H2080

    CAS  PubMed  Google Scholar 

  24. Wang YX, Crofton JT, Liu H, Sato K, Share L (1996) V2-receptor blockade enhances pressor response to vasopressin: gender difference. Life Sci 59(8):695–703. doi:10.1016/0024-3205(96)00351-7

    Article  CAS  PubMed  Google Scholar 

  25. Stachenfeld NS, Splenser AE, Calzone WL, Taylor MP, Keefe DL (2001) Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol 91(4):1893–1901

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The KORA research platform studies were initiated and financed by the Helmholtz Zentrum München—German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education, Science, Research and Technology and by the State of Bavaria. The KORA study group consists of A. Peters (speaker), J. Heinrich, R. Holle, R. Leidl, C. Meisinger, K. Strauch and their coworkers, who are responsible for the design and conduct of the KORA studies. We gratefully acknowledge the contribution of all members of field staffs conducting the KORA F4 study and thank all study participants. Furthermore, we thank Monika Offers and Katharina Antrack for excellent technical assistance. The study was supported by a research grant from the Virtual Diabetes Institute (Helmholtz Zentrum München) and the Clinical Cooperation Group Diabetes, Ludwig-Maximilians-University München and Helmholtz Zentrum München. Further support was obtained from the Federal Ministry of Health and the Ministry of Innovation, Science, Research and Technology of the state North Rhine Westphalia. Measurement of copeptin was partly funded by grants of the Karl-Wilder-Foundation (J.S.) and the Deutsche Diabetes-Gesellschaft (C.T.). The KORA F4 study was partly funded by a grant of the German Research Foundation (DFG) (RA-45913/3-1).

Conflict of interest

Cornelia Then, Bernd Kowall, Andreas Lechner, Christa Meisinger, Margit Heier, Wolfgang Koenig, Annette Peters, Wolfgang Rathmann and Jochen Seissler declare that they have no conflict of interest.

Statement of human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national, Ethics Committee of the Bavarian Medical Association) and with the Helsinki Declaration of 1975, as revised in 2008.

Statement of informed consent

Informed consent was obtained from all patients for being included in the study.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik IV, Diabetes Zentrum, Campus Innenstadt, Klinikum der Ludwig-Maximilians-Universität, Ziemssenstraße 1, 80336, Munich, Germany

    Cornelia Then, Andreas Lechner & Jochen Seissler

  2. Clinical Cooperation Group Diabetes, Ludwig-Maximilians-Universität München and Helmholtz Zentrum München, Munich, Germany

    Cornelia Then, Andreas Lechner & Jochen Seissler

  3. German Diabetes Center, Institute of Biometrics and Epidemiology, Leibniz Institute at Heinrich Heine University Düsseldorf, Düsseldorf, Germany

    Bernd Kowall & Wolfgang Rathmann

  4. Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany

    Christa Meisinger, Margit Heier & Annette Peters

  5. Medical Centre, Department of Internal Medicine II – Cardiology, University of Ulm, Ulm, Germany

    Wolfgang Koenig

  6. Research Unit of Molecular Epidemiology, German Research Center for Environmental Health, Neuherberg, Germany

    Annette Peters

Authors
  1. Cornelia Then
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernd Kowall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas Lechner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christa Meisinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Margit Heier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wolfgang Koenig
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Annette Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wolfgang Rathmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jochen Seissler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cornelia Then.

Additional information

Managed by Massimo Federici.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Then, C., Kowall, B., Lechner, A. et al. Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study. Acta Diabetol 52, 103–112 (2015). https://doi.org/10.1007/s00592-014-0609-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-014-0609-8

Keywords

Search

Navigation